"- they project forward the event rate they see during active enrollment or shortly thereafter to predict when they will hit the event number. Yes, it is a credibility issue, but given that it encompasses 90% of biotechs it isn't a real separator."
I call BS on this one. It is impossible to believe anybody even remotely familiar with clinical trials would make this mistake. What you are seeing is just intentional deciet by companies to keep the share price up.
"90% of biotechs spin clinical trial news" would be a fair statement.
News 
Market Data 
Discover 
